乳腺癌是女性最常见的恶性肿瘤，其转移复发是造成治疗失败并导致患者死亡的重要原因。因此寻找有效抑制乳腺癌复发的治疗方法就成为目前迫切需要解决的难题。近年来，快速发展的治疗性疫苗为抑制乳腺癌的转移与复发带来了希望。本研究前期已经采用乳腺癌肿瘤抗原HER-2与Survivin的优势表位作为靶点，制备DNA疫苗与蛋白疫苗通过静电耦合为纳米颗粒，随后将接种治疗荧光素酶标记的乳腺癌种植瘤小鼠模型，同时加入免疫佐剂GM-CSF以及IM，评价该新型疫苗的治疗作用，分析其颗粒化增加抗原摄取与提呈能力，以及同时激发细胞免疫与体液免疫情况，希望最终打破免疫耐受，激发机体特异性靶向乳腺癌细胞的免疫应答，有效清除转移的癌细胞，减少复发的几率，为提高患者的生存期与治愈率提供新的思路与实验依据。

Breast cancer is the most common malignancy. Metastasis and recurrence are important cause of treatment failure and death in patients. Thus, it's urgent to find effective treatments to prevent metastasis and recurrence of breast cancer. Recently, rapid development of therapeutic vaccines has brought hope for inhibiting the metastasis and recurrence of breast cancer. This research has used dominant epitope of breast tumor antigen HER-2 and survivin as targets, and generated DNA-protein nanoparticle. Then we will vaccinate and treat fluorescence-labeled metastatic breast cancer mouse model by the nanoparticles with immunoadjuvant GM-CSF and IM. After vaccination, we will evaluate the effects of the treatment and analyze the associated mechanisms including antigen presentation, cellular and humoral immune response. The aim of this research is to break the immune tolerance of breast cancer and stimulate specific anti-breast cancer immune response to eliminate metastatic malignancy. Our research will provide novel experimental evidence and strategy to the treatment of breast cancer.